As a standard of care, first-line (1L) targeted therapy for advanced EGFR mutation-positive NSCLC, osimertinib, is an effective and tolerable treatment that improves the prognosis of real-world patients with EGFR mutation-positive lung malignancies [11,12]. This evidence concerns the gene EGFR and medical procedure.